10-Q: Tyra Biosciences Advances Pipeline, Reports Increased Losses

Tyra Biosciences reported increased net losses and cash burn in Q3 2025, while advancing multiple clinical programs and maintaining a cash runway through at least 2027.

Summary

• Net loss for the three months ended September 30, 2025, increased to $29.9 million from $24.0 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $86.1 million from $60.9 million in the prior year period.
• Research and development expenses rose to $25.5 million for the quarter and $74.7 million for the nine months, reflecting increased clinical activity.
• General and administrative expenses increased to $7.5 million for the quarter and $21.5 million for the nine months, primarily due to higher compensation and headcount growth.
• Cash, cash equivalents, and marketable securities totaled $274.9 million as of September 30, 2025, down from $347.4 million at December 31, 2024.
• The company initiated patient dosing in the Phase 2 BEACH301 study for pediatric achondroplasia in August 2025 and the Phase 2 SURF302 study for NMIBC in June 2025.
• An Investigational New Drug (IND) application was cleared by the FDA in October 2025 for a Phase 2 study of dabogratinib in low-grade upper tract urothelial carcinoma (LG-UTUC), with study initiation expected in 2026.
• Interim data from the SURF301 study for metastatic urothelial carcinoma (mUC) showed 6 out of 11 (54.5%) FGFR3+ patients achieved a confirmed partial response at doses ≥ 90 mg once daily.
• Patient dosing commenced in April 2025 for the global Phase 1 SURF431 study evaluating TYRA-430 for hepatocellular carcinoma and other solid tumors.
• The company terminated its 2022 ATM Sales Agreement and entered into a new 2025 ATM Sales Agreement for up to $150.0 million, with no shares sold as of September 30, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is actively progressing its clinical pipeline with several new trial initiations and positive interim data for one program, the financial performance shows increased losses and cash burn. The cash runway through 2027 is a positive, but the explicit need for future capital raises and the significant decrease in cash balances are concerns. The overall picture is typical for a clinical-stage biotech, balancing R&D progress with financial consumption.

Positives

• Successful initiation of patient dosing in multiple Phase 2 clinical trials for dabogratinib (BEACH301 for pediatric achondroplasia and SURF302 for NMIBC).
• FDA clearance of an IND for dabogratinib in low-grade upper tract urothelial carcinoma (SURF303), expanding the clinical pipeline.
• Positive interim data from the SURF301 study for metastatic urothelial carcinoma, with 54.5% of FGFR3+ patients achieving a confirmed partial response at higher doses.
• Commencement of patient dosing for TYRA-430 in a global Phase 1 study (SURF431) for hepatocellular carcinoma.
• Maintained a strong cash position of $274.9 million, providing a projected cash runway through at least 2027.

Negatives

• Net loss significantly increased to $29.9 million for the quarter and $86.1 million for the nine months ended September 30, 2025, compared to prior periods.
• Cash, cash equivalents, and marketable securities decreased to $274.9 million as of September 30, 2025, from $347.4 million at December 31, 2024.
• Net cash used in operating activities increased to $71.5 million for the nine months ended September 30, 2025, indicating higher cash burn.
• Interest and other income, net, decreased by $1.5 million for the quarter and $3.4 million for the nine months, due to lower interest rates and reduced cash balances.

Risks

• The company may never succeed in achieving regulatory approval for any of its product candidates or any future candidates.
• The process of conducting necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming.
• Future capital requirements are substantial and depend on factors such as the initiation, scope, results, and costs of clinical trials, manufacturing, regulatory review, and intellectual property maintenance.
• Inability to raise additional funds or enter into collaborations when needed could force delays, limits, reductions, or termination of product development or commercialization efforts.
• Raising additional capital through equity or convertible debt securities could dilute existing stockholders' ownership interest.
• Debt or equity financing agreements may include covenants restricting the company's actions.
• Collaborations or similar arrangements may require relinquishing valuable rights to technologies, future revenue streams, or product candidates.
• The risk of delays or issues in development may be exacerbated by tariffs, trade policies, future pandemics, geopolitical instability, war, inflation, or rising interest rates.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses as it advances product candidates through preclinical and clinical trials, expands its pipeline, and incurs costs associated with being a public company. Management believes existing cash, cash equivalents, and marketable securities of $274.9 million as of September 30, 2025, will be sufficient to fund operating expenses and capital expenditures through at least 2027. The company does not expect to generate revenue from product sales for several years, if ever, and anticipates financing future cash needs through equity offerings, debt financings, or collaborations.

Management Comments

• "Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of September 30, 2025 will be sufficient to fund our operating expenses and capital expenditures through at least 2027."

Industry Context

Tyra Biosciences operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology in oncology and genetically defined conditions. The company's strategy of developing next-generation inhibitors designed to overcome toxicity and resistance liabilities of first-generation compounds aligns with a broader industry trend towards more targeted and effective therapies. The advancement of multiple clinical programs, including those for achondroplasia, bladder cancer, and hepatocellular carcinoma, positions Tyra within key therapeutic areas with significant unmet medical needs. The increased R&D spending is typical for a company at this stage, reflecting the high costs associated with clinical trial progression and drug discovery.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company is not currently subject to any material legal proceedings and no material legal proceedings are currently pending or threatened.

Related Party Transactions

• In connection with the February 1, 2024 private placement, the company issued 4,780,846 shares of common stock and pre-funded warrants to purchase 2,243,737 shares of common stock to related parties (Boxer Capital and RA Capital), resulting in aggregate gross proceeds of approximately $91.4 million.
• On October 18, 2024, the company entered into an exchange agreement with Boxer Capital and RA Capital (stockholders and related parties) to exchange common stock for pre-funded warrants.

Stakeholder Impact

• **Shareholders:** Experience dilution risk from potential future equity offerings and continued net losses. Positive clinical trial progress could lead to future value creation.
• **Employees:** Continued investment in R&D and general & administrative functions, including headcount growth, indicates stable to growing employment opportunities. Stock-based compensation remains a significant component of employee benefits.
• **Customers (future):** Progress in clinical trials for various cancer types and achondroplasia offers potential new treatment options.
• **Suppliers/Vendors:** Increased R&D expenses suggest continued engagement with contract research organizations (CROs), central laboratories, third-party manufacturers, and consultants.
• **Creditors:** The company's strong cash position and projected runway through 2027 provide a degree of financial stability, but ongoing losses and the need for future capital raises highlight long-term reliance on external funding.

Next Steps

• Report interim results from the safety sentinel cohort of the BEACH301 study in the second half of 2026.
• Report initial three-month complete response (CR) data from the SURF302 study in the first half of 2026.
• Initiate the Phase 2 SURF303 study for low-grade upper tract urothelial carcinoma (LG-UTUC) in 2026.
• Continue dose optimization in the SURF301 study for metastatic urothelial carcinoma.
• Continue the global Phase 1 SURF431 study for TYRA-430.
• Continue the Phase 1 SURF201 study for TYRA-200.
• Potentially raise additional capital through equity offerings, debt financings, or collaborations to fund future operations.

Key Dates

Recommendation

Tyra Biosciences is a clinical-stage biotech with a promising pipeline in FGFR biology, evidenced by multiple trial initiations and positive early data for dabogratinib in mUC. The cash runway through 2027 provides a reasonable buffer for ongoing operations. However, the company is experiencing significant and increasing net losses and cash burn, which is typical for its stage but necessitates future capital raises, posing dilution risk. The stock is a 'hold' for investors comfortable with high-risk, high-reward biotech investments, given the early-stage nature of most programs and the substantial capital requirements before potential commercialization. Further clinical data will be crucial for re-evaluation.

Keywords

Tyra Biosciences, Biotechnology, Clinical-stage, Oncology, FGFR, Dabogratinib, TYRA-300, Achondroplasia, Bladder Cancer, Urothelial Carcinoma, NMIBC, UTUC, mUC, TYRA-430, Hepatocellular Carcinoma, HCC, TYRA-200, Cholangiocarcinoma, ICC, Precision Medicine, SNP platform, SEC Filing, 10-Q, Financial Results, Clinical Trials, Drug Development